---
title: "Clinical Outcomes of Switching vs. Continuing Direct Oral Anticoagulants (DOACs) After Ischemic Stroke in Patients with Atrial Fibrillation in the US"
id: "medrxiv-7-clinical-outcomes-of-switching-vs-continuing-direct-oral-anticoagulants-doacs"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-clinical-outcomes-of-switching-vs-continuing-direct-oral-anticoagulants-doacs"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.06.26357356v1?rss=1"
published_at: "2026-07-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Clinical Outcomes of Switching vs. Continuing Direct Oral Anticoagulants (DOACs) After Ischemic Stroke in Patients with Atrial Fibrillation in the US
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-clinical-outcomes-of-switching-vs-continuing-direct-oral-anticoagulants-doacs
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.06.26357356v1?rss=1)
- **Published At:** 2026-07-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
Background: Clinical outcomes of switching versus continuing direct oral anticoagulant (DOAC) among atrial fibrillation (AF) patients who experienced an ischemic stroke despite receiving DOAC therapy are uncertain. Methods: We included patients with AF who were hospitalized for ischemic stroke (index stroke) between January 1, 2016, and June 30, 2022, while receiving DOAC therapy and who resumed DOAC within 90 days after discharge in the Merative MarketScan Commercial and Medicare databases. Patients were classified as DOAC-switched or DOAC-continued according to whether the DOAC agent changed or remained the same after the index stroke; secondary analyses considered individual DOACs. The primary outcome was recurrent ischemic stroke; secondary outcomes included major bleeding and a composite outcome (bleeding or ischemic stroke). Propensity score-based overlap weighting and weighted Cox models were used to estimate adjusted hazard ratios (aHRs). Results: A total of 1175 patients were eligible for the study, of whom 970 (82.6%) continued and 205 (17.4%) switched DOAC therapy.
## Clinical Analysis & Structured Key Points
medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 09 Jul 2026. The item focuses on Clinical Outcomes of Switching vs. Continuing Direct Oral Anticoagulants (DOACs) After Ischemic Stroke in Patients with Atrial Fibrillation in the US. Review the original article for the full source wording and details.
## Related Clinical Research

- [New oral anticoagulants linked to slower cognitive decline in Alzheimer’s patients with AFib](https://medichelpline.com/clinical-feed/medical-news-today-0-new-oral-anticoagulants-may-help-slow-cognitive-decline-in-alzheimer-s-disease.md)
- [NOAC monotherapy vs NOAC+clopidogrel by age in AF patients with drug-eluting stents](https://medichelpline.com/clinical-feed/pubmed-42546025.md) (DOI: 10.1093/ageing/afag224)
- [Bleeding Risk in Atrial Fibrillation: Apixaban or Rivaroxaban With Diltiazem vs Metoprolol](https://medichelpline.com/clinical-feed/annals-of-internal-medicine-87-the-risk-for-bleeding-in-patients-with-atrial-fibrillation-from-concomitant-use-of-apixaban-or-rivaroxaban-with-diltiazem-compared-with-metoprolol.md)
- [Goodbye “Massive” and “Submassive”](https://medichelpline.com/clinical-feed/litfl-5-goodbye-massive-and-submassive-.md)
- [Rivaroxaban After Catheter Ablation for Atrial Fibrillation Compared With Aspirin](https://medichelpline.com/clinical-feed/annals-of-internal-medicine-32-after-successful-catheter-ablation-for-af-rivaroxaban-did-not-reduce-a-composite-of-stroke-or-systemic-embolism-vs-aspirin-at-36-mo.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.